Chinese Nucleic Acid Drug Developers Dominate October VC/PE Funding
Sirius Therapeutics’ $60m series B signified venture capital firms’ reviving interest in Chinese developers of nucleic acid drugs. Meanwhile, Angitia Biopharmaceuticals’ $46m series B extension round underscored investors’ attention to the musculoskeletal diseases area.
You may also be interested in...
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
Topics in this latest Chinese-language podcast include the US approval of Chinese innovative drugs including Junshi’s anti-PD-1 antibody toripalimab, Sanofi’s deal with BioMap for AI-powered drug discovery, Chinese companies' third-quarter results and the Biden-Xi summit on the sidelines of APEC and its implications for bilateral regulatory dialog.